Global Hepatitis Drugs Market 2015-2019
Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption, and autoimmune diseases. The viruses that cause hepatitis are of several types: A, B, C, D, E, and G. The most common type of hepatitis viruses are A, B, and C. Hepatitis viruses can cause either acute or chronic infections.
Technavio's analysts forecast the global hepatitis drugs market to grow at a CAGR of 17.1% over the period 2014-2019.
Covered in this report
The report includes the present scenario and the growth prospects of the global hepatitis drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of hepatitis.
Technavio's report, Global Hepatitis Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as the segmentation. The report includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Global Hepatitis Drugs Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Hepatitis Drugs Market: F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis and Vertex Pharmaceuticals
Other Prominent Vendors in the market are: Abbvie, Achillion Pharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies and Mitsubishi Tanabe Pharma
Commenting on the report, an analyst from Technavio’s team said: “The global hepatitis drugs market in emerging countries such as India, Brazil, China, and Russia is expected to grow at a rapid pace during the forecast period owing to an increase in patient population and public awareness about hepatitis. Drug manufacturers focus on these countries with the motive of launching new products and penetrating these markets.”
According to the report, early detection of hepatitis is important in reducing the chances of developing liver infections, which can prevent extensive liver damage. Various government and non-government organizations organize awareness campaigns and other programs to educate people about the disease and therapeutic measures available.
Further, the report states that the patent expiration of approved drugs is expected to have an adverse impact on the market, slowing down market growth during the forecast period.
F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Vertex Pharmaceuticals, Abbvie, Achillion Pharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Mitsubishi Tanabe Pharma